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ABSTRACT
The goal of the present study was to develop and validate a
new canine model of inflammation. The motivation was to make
available a scientifically appropriate and ethically acceptable
model to conduct pharmacokinetic/pharmacodynamic investi-
gations for testing nonsteroidal anti-inflammatory drugs in
dogs. A kaolin-induce paw inflammation model previously de-
veloped in cats was adapted to the dog. The paw inflammation
developed within a few hours, reached maximum values 24 h
and up to 3 days after kaolin administration, and then progres-
sively resolved over 2 months. Five end points of clinical inter-
est (body temperature, creeping time under a tunnel, paw with-
drawal latency to a standardized thermal stimulus, lameness
score, and vertical force developed during walking on a force
plate) were measured regularly over the next 24 h and beyond
to characterize the time development of the inflammation either
in control conditions (placebo period) or after the administration
of meloxicam (test period) according to a crossover design.
Pharmacodynamic data were modeled using an indirect re-
sponse pharmacokinetic/pharmacodynamic model. This model
described three effects of meloxicam, namely, classic anti-
inflammatory, analgesic, and antipyretic effects. The mean
plasma meloxicam IC50 values were 210 ng/ml for the anti-
pyretic effect, 390 ng/ml for the analgesic effect, and 546 ng/ml
for the vertical force exerted by the paw on the ground as
measured by force plates. These in vivo IC50 values require
approximately 80 (antipyretic effect) to 90% (all other effects)
cyclooxygenase-2 inhibition as calculated ex vivo whole-blood
assay data.
Introduction
Few preclinical studies have attempted to model plasma
concentration-time profiles with the time course of nonsteroi-
dal anti-inflammatory drug (NSAID) effects in small carni-
vores (Toutain et al., 2001; Giraudel et al., 2009). A requisite
to carry out a pharmacokinetic/pharmacodynamic (PK/PD)
dose determination is the availability of an animal model in
which the measured end points are clinically relevant, mea-
surable with good metrological performances, and long
enough to prevent (or minimize) confusion between the ac-
tion of the investigated NSAID and the natural time devel-
opment of the inflammatory process. Currently, only acute
knee joint synovitis using intra-articular injection of sodium
urate crystals has been well described in dogs, and its appli-
cation to the preclinical evaluation of different NSAIDs is
now well documented (Cross et al., 1997). However, this
model is of too short in duration (less than 24 h) to allow a
PK/PD investigation for drugs having a duration of action of
approximately 24 h. Likewise, the carrageenan-induced
acute paw inflammation in dogs model proposed by Brooks et
al. (1991) was too short in duration for this purpose. This is
why we developed a Freund’s complete adjuvant osteoarthri-
tis model, resulting in a sustained and relatively stable sec-
ondary inflammatory response (Botrel et al., 1994; Toutain et
al., 2001). This Freund’s model was scientifically attractive,
allowing repeatable measurements of relevant clinical end
points, but the inflammation was irreversible, and it was
mandatory to sacrifice dogs for ethical reasons. Because we
are committed to a program of rehabilitating dogs by donat-
ing them as companion animals at the end of the trials, we
adopted the 3R principles to avoid unnecessary suffering to
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animals [i.e., replace (use alternatives to animal testing
whenever possible), reduce (improve existing methods so that
fewer laboratory animals are required in an experiment), and
refine (improve existing methods so that animals experience
as little discomfort and distress as possible)]. The PK/PD
approach itself can be considered as a refinement of a dose
titration allowing a reduction in the required number of
animals to establish a full dosage regimen (dose and dosing
interval), but to achieve our ultimate goal of rehabilitating
experimental animals, it was necessary to develop and vali-
date a new reversible inflammation model in dogs. Such a
model was developed recently in cats (Giraudel et al., 2005a).
It consisted of administering kaolin (an inert foreign body) as
a phlogistic agent in the paw. The resulting inflammation
was sustained between 1 and 3 days after kaolin injection,
allowing administration of the NSAID on day 2. The model
was found to be suitable for simultaneously studying the
analgesic, anti-inflammatory, and antipyretic effects of
NSAIDs in cats by measuring different end points such as
body temperature or gait scoring (Giraudel et al., 2005a,b).
Moreover, because the kaolin was administered extra-articu-
larly, the inflammation progressively vanished with either
the physical wasting of the administered kaolin by direct
skin exudation or the encystment of the remnant kaolin
fraction, and within a few weeks, most animals returned to
the control condition without any apparent sequelae.
The objective of the present study was to transfer and
validate this reversible inflammation model in dogs, a species
used extensively in regulatory studies in both human and
veterinary medicine. We selected meloxicam as a test
NSAID, because it is a well established NSAID in dogs (Ara-
gon et al., 2007) and also used in man.
Materials and Methods
Animals. Eight healthy Beagle dogs (two females and six males)
were selected after clinical examination and biochemical analysis. The
body weights and ages of the dogs ranged from 12.5 to 17.5 kg and 1 to
3 years, respectively. Between experimental phases, the dogs were
housed in large boxes. During the different phases of the trials, the
animals were kept in individual stainless steel cages in a controlled
environment. On the days of the measurements, the dogs were placed in
their cages at least 2 h before any measurement. Dogs were fed each
evening after the last measurements with 250 50 g of commercial dry
food (medium; Royal Canin, Aimargues, France). Animal care and con-
duct of the study were performed according to the Guide for the Care
and Use of Laboratory Animals (Institute of Laboratory Animal Re-
sources, 1996). The study has been carried out in accordance with the
Declaration of Helsinki and with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the U.S. National
Institutes of Health. The protocol was approved by the Animal Experimen-
tation Ethics Committee of Midi-Pyrenees. The study was performed in
compliance with the Principles of Good Clinical Practice (CVMP/VICH/
595/98; http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/10/WC500004343.pdf) and according to the
Guideline for the Conduct of Efficacy Studies for NSAIDs (EMEA/CVMP/
237/01; http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/10/WC500004423.pdf). Because the model is to-
tally reversible without sequelae, all of the dogs that participated in this
trial were rehabilitated as companion animals at the end of the study.
Animal Preparation and Induction of Inflammation. Both
hind paws were shaved from the toes up to the hock joint, and targets
were marked for the pain assessment and paw circumference
measures (Fig. 1).
The preparation of kaolin (hydrated aluminum silicate; Sigma-
Aldrich, St. Louis, MO) was done using standardized procedures
(Giraudel et al., 2005b). For the induction of inflammation, the dogs
were given a general anesthetic with alfaxalone 3 mg/kg (Alfaxan;
Ve´toquinol, Lure, France), and anesthesia was maintained with iso-
flurane (2% v/v; Aerrane; Baxter, Lessines, Belgium). A local anes-
thetic was added: approximately 2.5 ml of lidocaine was injected
subcutaneously into the paw (Lurocaïne; Ve´toquinol), after which
1.85  0.10 g of kaolin was injected under aseptic conditions subcu-
taneously at eight different points in the metatarsal pad. The total
volume of the kaolin suspension (25% w/w) was 6.4 ml.
Experimental Design. The eight dogs and the investigators
were trained regularly for all of the experimental conditions and all
of the end point measurements for at least 1 month. This training
period guaranteed the eligibility for the trial of the eight selected
dogs and the investigators’ skills. The trial consisted of two phases.
In the first phase, the metrological performances of the different end
points were assessed in all of the dogs. Investigated end points were
body temperature, paw circumference, time to perform a creeping
test under a tunnel, vertical force of the paw on force plates, and
thermal pain threshold. Three series of end point measurements
were obtained each day and for 5 consecutive days, and the repeat-
ability and reproducibility of the different end points were computed.
Lameness scoring was not validated during this first control phase
because all of these control measurements were obtained in nonin-
flammatory conditions. Then, during a second phase, a two-period,
two-sequence crossover design was carried out. The eight dogs were
allocated randomly into four pairs of the same sex and of similar
body weight. Dogs of each pair then were allocated into one of two
groups (sequences) corresponding to the order of the administration
of the test articles (placebo then NSAID or, conversely, NSAID then
placebo). The washout period between the two periods of the cross-
over was 8 weeks. Kaolin inflammation was induced for each dog of
a pair and in the two periods (right paw period 1 and left paw period
2). The experiment was blinded to the investigators. The placebo
corresponded to a sham meloxicam administration. Meloxicam
(Metacam; Boehringer Ingelheim Vetmedica, Ingelheim/Rhein, Ger-
many) was administered by the subcutaneous route 26 h after kaolin
inflammation induction. The dose of meloxicam administered was
the marketed dose for dogs (0.2 mg/kg). Blood samples were obtained
from the jugular vein by direct puncture at time 0 (control) and then
5, 15, 30, and 60 min and, 2, 4, 6, 9, 12, 21, 48, and 72 h after the test
article administration (meloxicam or placebo). Before kaolin admin-
istration, the PD end points were measured twice the same day and
then twice at 22 and 24 h after the induction of the kaolin inflam-
mation. Subsequently, the PD end points were measured at 30 min,
2.25, 4, 6, 9, 12, 15, 18, 21, 30, and 48 h, and 3, 4, 5, 6, 7, 10, 14, 17,
21, and 24 days after test article administration (i.e., placebo or
Fig. 1. Cutaneous reference marks on the hind paw of the dog for the
circumference ( ) and analgesia (F) measurements and view of the
different sites of subcutaneous kaolin injection (3).
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meloxicam). Two supplementary measures were obtained on the
35th day after test article administration (body temperature and
paw circumference) and at 64 days (paw circumference).
End Point Measurements. The six clinical end points selected to
assess inflammation were as follows: 1) body temperature (a single
measurement was obtained at each time using an electronic ther-
mometer), 2) paw circumference (duplicate measures per time point)
measured just above the pad using a measuring tape (DMC, Colmar,
France), 3) lameness scored using a numerical rating scale as devel-
oped by Giraudel et al. (2005b) (Table 1), 4) creeping time (i.e., the
time required by the dog to creep under a 6-m-long tunnel) measured
in triplicate at each measurement time and with the mean time
computed, 5) vertical normalized force (i.e., the maximal vertical
force applied on the ground by a hind limb measured with force
plates) (SATEL Ve´to; Patrick Savet, Blagnac, France); for each mea-
surement time, three valid measures were recorded and the mean
normalized to the dog’s body weight (Fmax/b.wt., kg/kg) used in the
data analyses, and (6) pain as assessed using a hind paw thermal
escape model (Hargreaves et al., 1988). The model consisted of ex-
posing the hind limb to a light beam delivered by a Hargreaves
apparatus (model 390; IITC Inc., Woodlands Hills, CA) (Giraudel et
al., 2005b). This equipment has a light source (halogen 24 V, 150 W)
that creates and controls heat intensity. A heat intensity correspond-
ing to 15% of the peak heating value of 150 W was selected. Dogs
were placed on a table equipped with a glass top that enabled the
beam to be applied from underneath onto a target selected area on
the plantar surface of the hind limb. Dogs were trained to stay quiet
in control conditions in this environment with minimal manual re-
straint. When applying the heat stimulus to the top of the metatarsal
pad (Fig. 1), a lateral leg movement or any sign of retraction of the
paw was considered as a response, and the pain stimulation was
stopped immediately. A maximal stimulation time of 90 s was used
to prevent any tissue damage through burning. The paw withdrawal
time (in seconds) was measured. For each trial, three measures were
recorded per measurement time, and the mean of the three measures
was used in the data analysis.
Analysis of Meloxicam in Plasma. Plasma samples were ana-
lyzed by a high-performance liquid chromatography method using
UV detection. In brief, an internal standard (piroxicam) and meloxi-
cam were extracted from the plasma by solid-phase extraction. The
high-performance liquid chromatography apparatus consists of a
pump system equipped with an automatic injector and an UV detec-
tor (360 nm). Separation was achieved by reverse-phase column
(150  2.0 mm, 3 m; Diphenyl Pursuit XRs; Varian, Lake Forest,
CA) using a guard column (4.0  2.0 mm; Phenyl). The mobile phase
was a 50:50 mixture of water with 1% acetic acid and acetonitrile
(Sigma-Aldrich) at a flow rate of 0.2 ml/min. Under these conditions,
meloxicam (Sigma-Aldrich) and piroxicam (Sigma-Aldrich) were
eluted at retention times of 7.2 and 5.6 min, respectively. The
method was linear over the calibration range from 10 to 1500 ng/ml
using a linear model weighted by 1/X2. Within-day and day-to-day
coefficients of variation were less than 15%, and the accuracy ranged
from 101 to 103%, indicating appropriate precision and accuracy for
the analytical method. The lack of interference from endogenous
compounds was verified on blank plasma from untreated dogs, es-
tablishing the specificity of the method. The validated limit of quan-
tification was 10 ng/ml.
Data Analysis. PK and PK/PD modeling were performed by
least-squares regression analysis using WinNonlin Professional
software (WinNonlin, version 5.2; Pharsight Corporation, Moun-
tain View, CA).
Individual plasma meloxicam concentrations (ng/ml) were fitted to
polyexponential equations. The data points were weighted by the
inverse of the squared-fitted value. The number of exponents (two or
three) needed to obtain the best fit for each data set was determined
by the Akaike’s information criterion (Yamaoka et al., 1978) and by
inspection of the plot of residuals. On the basis of this approach, a
biexponential equation corresponding to a monocompartmental
model for extravascular administration with a lag time was selected
(eq. 1).
C(t) 
FDk01
Vk01 k10
expk10 t tlag expk01 t tlag
(1)
where C(t) is the meloxicam plasma concentration (ng/ml) at time t
(h), V/F (l/kg) is the apparent volume of distribution, k01 (1/h) is the
rate constant of the initial ascending phase, k10 (1/h) is the rate
constant of the terminal phase, and D is the meloxicam dose (mg/kg).
The parameters (V/F, k01, k10, and tlag) were estimated.
For PK/PD modeling, raw measured data were used directly as
dependent variables for body temperature, lameness score, and
creeping time. Because kaolin decreased the vertical force exerted on
the force plates or the paw withdrawal time, these variables were
transformed to be expressed as a percentage of reduction (100% is
the maximal effect observed after kaolin administration) to use the
same PK/PD model for all of end points. Individual PK/PD relation-
ships were described using indirect PD response models (Dayneka et
al., 1993). In these models, the measured response (R) is assumed to
result from factors controlling either the input or the dissipation of
the measured response. Different models were explored, including
precursor-dependent indirect response models (Sharma et al., 1998),
to capture not only the main effect of meloxicam but also the devel-
opment of rebound phenomena, which were observed after meloxi-
cam action had ceased. Finally, PD data were described by the
following sets of differential equations (eqs. 2–4).
In the control condition (i.e., before kaolin administration), for
both periods
dR⁄dt kin koutR (2)
where dR/dt is the rate of change of the response over time, kin
represents the zero-order rate constant for the production of the
response, and kout is the first-order rate constant for the loss of the
response.
The time development of the kaolin action, noted as kao(t), on the
different measured responses was incorporated additively to kin in
the model described by eq. 3
dR⁄dt kin kaot koutR (3)
where kao(t) is the zero-order input rate function (same units as kin)
representing the action of the kaolin accounting for the temporal
increase in the response after kaolin administration. Such a model
already has been selected by other researchers for the PK/PD mod-
eling of the antipyretic effect of naproxen in a model of endotoxin-
challenged rats (Josa et al., 2001). After consideration of the inverse
U shape of the time development of the responses in the placebo
period, kao(t) was modeled using an empirical biexponential equa-
tion of the form (eq. 4)
kaot P1expP2t tlag expP3t tlag (4)
TABLE 1
Numerical rating scale for the evaluation of lameness in the inflamed
paw in dogs
Score Definition of the Lameness Score
0 No lameness
1 Barely detectable lameness over most of the observation period
2 Mild lameness, substantial weight bearing
3 Moderate lameness, minimal weight bearing
4 Severe lameness, the animal uses his paw (walking movement
initiated and/or touches lightly the ground) but does not bear
weight
5 The animal could not be more lame, refuse to move and/or
avoid any contact of the inflamed paw with the ground
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with P1 the intercept (response unit per hour), P2 (1/h) the slope of
the decreasing phase of the kaolin action, P3 (1/h) the rate constant
reflecting the increasing phase of the kaolin action after kaolin
administration, and tlag the time of kaolin administration. The three
parameters (P1, P2, and P3) were estimated simultaneously with the
PD parameters of ultimate interest (i.e., kin, IC50, and kout; see
below), and the lag time was fixed at the actual time of kaolin
administration for both placebo and test periods.
The effect of meloxicam (melox) was described as the consequence
of the inhibition of the phlogogenic effect of kaolin, that is, kao(t) and
was incorporated in eq. 3 as (eq. 5)
dR⁄dt kin kaot 1melox koutR (5)
where melox is the classic fractional Imax function of the form (eq. 6)
Melox
Imax Ctn1
IC50A
n1  C(t)n1
(6)
where melox is a Hill equation in which C(t) (ng/ml) is the meloxicam
plasma concentration at time t (h) as obtained by fitting eq. 1, IC50A
(ng/ml) is the meloxicam plasma concentration producing half the
maximum meloxicam effect (i.e., 50% of Imax), Imax is a scalar with a
maximal value of 1, and n1 is the slope of the concentration-effect
relationship. For the test period, it was nearly always observed that
after the meloxicam action vanished the response increased again
(indicating that kaolin action was still present), and unexpectedly,
there was an overshoot of the response compared with measures
made at the same time in the placebo period. To take into account
this second effect of meloxicam on the fate of the kaolin inflammation
itself, we rendered time-dependent P2, the rate constant reflecting
the kaolin inflammation disappearance (see eq. 4), according to eq. 7
P2, melox P2 1 C(t)n2IC50Bn2  Ctn2 (7)
where P2,melox is the time-dependent rate constant reflecting the
disappearance of the kaolin action, the value of which was controlled
by the plasma meloxicam concentration [C(t)] throughout a frac-
tional Imax function with IC50B being the meloxicam plasma concen-
tration halving P2. Equation 7 says that P2,melox decreases when
the plasma meloxicam concentration increases (i.e., meloxicam is
delaying the disappearance of the kaolin action, and the natural time
course of inflammation resumes when meloxicam is no longer pres-
ent) (see Discussion).
Finally, 10 parameters were estimated by simultaneously fitting
the placebo period (with data collected before and after kaolin ad-
ministration) and the test periods (with data collected before kaolin
administration, after kaolin administration but before meloxicam
administration, and after meloxicam administration), namely, kin,
kout, IC50A for the main anti-inflammatory effect of meloxicam, IC50B
for effect of meloxicam on the time development of the kaolin, n1, n2,
Imax, and P1 to P3.
Through the use of mean PK and PD parameters, simulations
were performed to predict the time development of the response for
kaolin alone or kaolin followed by meloxicam for each end point and
for doses ranging from 0.05 to 2 mg/kg. Data from all of the individ-
ual animals were used to compute the mean PK parameters, but only
those dogs with an acceptable PD fit (six to eight animals depending
on the PD end points) were taken into account for the calculation of
the mean PD parameters.
For each simulation, the maximal response obtained for each
response profile was used as a metric to further characterize the
dose-response relationship. Then, the dose (mg/kg) versus simulated
maximal response was fitted using a classic inhibitory sigmoid model
(model of the form of eq. 8)
Effect  Baseline 1 ImaxDosenED50n 	Dosen (8)
where ED50 is the dose giving half the maximal response and n is the
slope of the dose-response relationship.
To estimate the extent of cyclooxygenase (COX)-1 and COX-2
enzyme inhibition corresponding to the different estimated in vivo
IC50 values, we computed the percentage of COX-1 and COX-2 inhi-
bition from ex vivo results of a whole-blood assay performed in
another group of Beagle dogs. COX-1 activity was determined by
measuring serum thromboxane B2 synthesis in blood samples.
COX-2 activity was determined by measuring prostaglandin E2 syn-
thesis in blood samples incubated at 37°C for 24 h in the presence of
lipopolysaccharide. The data were fitted to Hill plots, and the slope
(
) and IC50 values were calculated. For prostaglandin PGE2 inhi-
bition, 
was estimated to be 0.986, and the IC50 value was estimated
to be 0.1454 M (51 ng/ml); corresponding values for thromboxane B2
were 1.024 and 1.215 M (427 ng/ml). Through the use of these
parameters kindly provided by Novartis, the Imax model was used to
estimate the extent of COX-1 and COX-2 inhibition corresponding to
our in vivo estimated IC50 value.
Statistical Analysis. Metrological performances of the different
end points were assessed using the following statistical model (Sys-
tat 10; Systat Software, Inc., San Jose, CA)
Yijk  AiDj Tk A * Dij A * Tik A * Tjk εijk
where Yijk is the end point value for animal i at day j and time k, 
is the overall mean, Ai is the animal factor, Dj is the day factor, Tk is
the measurement time factor, CDij, CTik, and DTjk are the corre-
sponding interactions, and εijk is the residual error for i  1 to 8, j 
1 to 5, and k  1 to 3.
All of the variables in this model were considered as fixed factors,
and a factor was considered significant when p  0.05.
An analysis of variance was used to test the significance of the
different factors and to calculate the repeatability of measurements
(as a coefficient of variation) using the residual of the model:
Repeatability: CV%
Mean square of residual error
mean  100
Repeatability is the highest level of precision obtained in a given dog
for a given day and a given measurement time. Reproducibility (as a
coefficient of variation) was calculated based on all of the values
recorded during the five days of the study:
Reproducibility: CV% 
SD
mean  100
Reproducibility (always higher than repeatability) is the lowest level
of precision encompassing all of the factors of variability in a
measurement.
The PK and PD results are presented as mean or median and S.D.
For the half-lives, the harmonic mean was calculated. An ANOVA
analysis was used to test the significance of the difference between
different IC50 values.
Results
Metrological Performance of the PD End Points (Re-
peatability and Reproducibility). The results are sum-
marized in Table 2. The dog factor was highly significant for
all of the end points (p  0.001, data not shown), reflecting
the interanimal variability and justifying a crossover design
to assess the dogs’ responses in both placebo and test condi-
tions. For several end points, there were significant animal
per day interactions, meaning that the day-to-day variation
that could be observed for an end point measurement did not
follow a systematic trend as would have happened if a “train-
ing” effect had occurred during our validation tests. The
measurement time (within day) effect was significant for the
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body temperature. This observed trend was interpreted as
reflecting an endogenous circadian rhythm, the body temper-
ature in the afternoon always being higher than that in the
morning. This possible confounding factor was not considered
in our PK/PD modeling because the absolute difference asso-
ciated with this factor was only 0.1°C.
Repeatability (i.e., variability within a given measurement
time) was appropriate for all of the end points (5% for the
measures of creeping time and vertical normalized maximal
force and 0.5% for measures of body temperature and paw
circumference). For the withdrawal time measuring analge-
sia, the CV of repeatability was 15.1%, which is low consid-
ering the expected amplitude of the kaolin and meloxicam
effect. Reproducibility (i.e., the overall variability between
dogs, days, and measurement times) was 5% for the mea-
sures of body temperature and paw circumference, 10% for
the measure of the vertical normalized maximal force, and
25% for the creeping time and the paw withdrawal time.
The animal factor was the main contributor to the overall
reproducibility, thus justifying the use of a crossover design
for this kind of investigation rather than a parallel design.
PK Results. The meloxicam plasma concentration profile
after subcutaneous administration of 0.2 mg/kg was inter-
preted as a monocompartmental model with a first-order rate
constant of absorption and a lag time (Fig. 2). The apparent
total plasma clearance (Cl/F, clearance scaled by the un-
known bioavailability) was low (6.33  1.95 ml  h1  kg1),
and the apparent volume of distribution (V/F, volume of
distribution scaled by the unknown bioavailability) was
small 192.1  34.4 ml/kg. Peak meloxicam plasma concen-
tration (890.2  166.4 ng/ml) was attained at 5.97  1.73 h
after administration, and the harmonic mean of the apparent
half-life of absorption was 1.32  0.59 h. The harmonic mean
of the terminal half-life was relatively high at 21.26  4.83 h.
Time Development of the Kaolin Paw Inflammation
Model with and without Meloxicam Administration.
Figure 3 illustrates the time course and magnitude of the
inflammatory response for the six investigated end points in
both placebo and treated conditions. The end point values
reached maxima 22 and 24 h after the kaolin injection. For
the placebo period (without meloxicam), body temperature,
creeping time, and paw withdrawal time still were altered
56 h after kaolin administration (spontaneous improvement
was 50%, a 100% improvement meaning return to the
prekaolin administration condition). Paw edema (measured
by the paw circumference) disappeared slowly, a delay of 15
days being necessary to reduce the kaolin-induced edema by
approximately 50%. The vertical force exerted by the hind
limb still was decreased by approximately 50% on the 10th
day after the kaolin administration, indicating a rather sus-
tained inflammation that enables NSAID effects to be fol-
lowed over a prolonged time period. However, the natural
time course of the inflammation was not stable enough to be
ignored when modeling the NSAID effect, and a crossover
design including a placebo period was mandatory to assess
the net effect of the NSAID (see Discussion). In terms of
animal welfare, it was observed that for the six investigated
end points an improvement superior to 85% was observed
after kaolin administration between the 14th and 17th days
(body temperature), the 24th and 35th days (paw circumfer-
ence), the 17th and 21st days (lameness score), the 10th and
14th days (creeping time), the 10th and 14th days (vertical
force of the paw exerted on the ground), and the 7th and 10th
days for the allodynia as assessed by paw withdrawal time.
In treated conditions (after a subcutaneous injection of
meloxicam at a dose of 0.2 mg/kg), a clear-cut drug response
was obtained for all but one end point, namely, paw circum-
ference. The unresponsiveness of paw circumference to
meloxicam was expected (see Discussion) and was not con-
sidered for further analysis. The mean time of the peak
response occurred for all of the end points between 4.6 and
7.3 h after meloxicam administration. The mean time of the
maximum decrease in body temperature was slightly shorter
(4.6 h) than the mean time of the peak response for other end
points. The mean paw withdrawal time obtained 6 h after
meloxicam administration (16.54  6.44 s) was similar to the
mean baseline withdrawal time without inflammation
(16.79  3.03 s), indicating that complete suppression of
allodynia was achieved with 0.2 mg/kg meloxicam. The body
temperature, lameness score, creeping time, and vertical
force of the paw values did not return to baseline values, the
maximal percentages of improvement being of 70, 59, 79, and
66%, respectively. An average duration of drug response was
observed for approximately 20 h for all of the end points.
After completion of the meloxicam action, the time course of
the inflammation did not return to the one observed at the
same time during the placebo period, but rather there was for
all of the measured end points an overshoot from the 21st
hour after meloxicam administration and the following 2 or 3
days.
Fig. 2. Spaghetti plot of meloxicam plasma concentration (ng/ml) versus
time in eight dogs after a subcutaneous administration of meloxicam (0.2
mg/kg).
TABLE 2
Repeatability and reproducibility of the selected endpoints
Results are expressed as the coefficient of variation of repeatability and
reproducibility (%).
Repeatability
CV
Reproducibility
CV
%
Body temperature 0.41 0.5
Circumference of the paw 0.44 3.2
Creeping time under a tunnel 4.66 24.2
Vertical normalized maximal force of
the paw as obtained with a force
plate
3.26 7.1
Paw withdrawal time to a heat
stimulus
15.14 20.1
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PK/PD Analysis. Figure 4 shows the fit of the responses
for all of the end points (body temperature, lameness score,
creeping time, vertical force of the paw on the ground, and
paw withdrawal time) for a representative dog. For the eight
dogs investigated and the five measured end points, a suc-
cessful fit was obtained for 34 of the 40 recorded time courses.
Table 3 gives the mean PD parameters for all of the end
points. Mean values of IC50A for the meloxicam effect on
kao(t) ranged from 210 ng/ml for body temperature to 546
ng/ml for the vertical force measured by the force plate. The
IC50A value for body temperature was lower than the other
IC50A values, but the differences were not significant
Fig. 3. Time course of six end points
(mean  S.D.). A, body temperature, paw
circumference, and lameness score. B,
creeping time and vertical normalized
force of the paw and pain expressed as
withdrawal time of the paw. Data ob-
tained in eight dogs in treated (meloxi-
cam, 0.2 mg/kg) and placebo conditions
after an injection of 1.85 g of kaolin in the
hind paw. T are control values obtained
before kaolin administration; T	 are con-
trol values obtained after administration
of kaolin but before meloxicam or placebo
administration.
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(analysis of variance, p  0.05). The interanimal variabil-
ity of the estimated IC50A value was estimated using a
coefficient of variation that ranged from 28 (for analgesia)
to 86% (creeping time) with intermediary values for the
other end points.
The meloxicam sensitivity (i.e., the slope of the concen-
tration-effect relationship) was relatively high for all of the
end points (from 2.56 to 4.37), indicating that the effect
was rapidly reaching Imax with increasing meloxicam
plasma concentrations.
Fig. 4. Observed (F, E) and fitted values during the placebo (E, -• -• - ) and the test period (F, __) of the five investigated end points in a representative
dog after a single subcutaneous meloxicam administration at a concentration of 0.2 mg/kg. A–E, body temperature (°C) (A), lameness score (B),
creeping time (s) (C), vertical force exerted by the paw expressed as a percentage of the maximal observed response to kaolin (D), and paw withdrawal time
expressed as a percentage of the maximal observed response to kaolin to a heat stimulus during the placebo and the treated (meloxicam, 0.2 mg/kg) period
(E). Kaolin was administered at 71 and 71.967 h during the test and placebo period, respectively; meloxicam was administered at 97.5 h.
TABLE 3
Estimated mean pharmacodynamic parameters describing meloxicam anti-inflammatory, analgesic, and antipyretic effects after a subcutaneous
administration of meloxicam at a dose of 0.2 mg/kg to eight dogs
Units Definition Body Temperature(CV%)
Lameness
Score (CV%)
Creeping
(CV%)
Force Plate
(CV%)
Analgesia
(CV%)
kin Response per
hour
Zero-order rate constant for
production of the response
94.6 (14) 0.0057 (25) 13.8 (57) 7.64 (119) 43 (63)
IC50B Nanograms per
milliliter
Plasma meloxicam IC50 on the
time development of kaolin
inflammation
69 (51) 56 (28) 72 (27) 68 (37) 61 (28)
n2 No unit Hill coefficient associated with IC50A 2.61 (51) 1.87 (23) 2.91 (83) 2.27 (74) 1.13 (77)
kout h
1 First-order rate constant for loss of
response
2.51 (14) 4.99 (49) 3.45 (63) 3.03 (123) 5.37 (45)
ImaxA No unit Maximal possible clinical effect
(between 0 and 1)
0.84 (11) 0.82 (16) 1 (N.A.) 1 (N.A.) 1 (N.A.)
IC50A Nanograms per
milliliter
Plasma meloxicam concentration for
ImaxA/2 for the clinical endpoints
210 (64) 466 (55) 400 (86) 546 (64) 390 (65)
n1 No unit Hill coefficient associated with IC50B 4.37 (66) 3.93 (85) 2.56 (91) 3.03 (95) 3.88 (105)
P1 Same as kin Parameters characterizing time
development of kaolin inflammatory
action (see eq. 4)
5.10 (35) 24.3 (46) 32.8 (42) 303 (125) 483 (56)
P2 h
1 0.023 (47) 0.0038 (100) 0.015 (86) 0.0052 (130) 0.0112 (101)
P3 h
1 0.96 (20) 1.05 (10) 0.94 (16) 0.71 (72) 0.95 (21)
N.A., not applicable.
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In the current modeling, meloxicam developed a second
action through a modulation of kao(t). The estimated IC50B
values for this secondary effect were systematically lower
than the corresponding IC50A values of the main effect of
meloxicam [mean IC50A/IC50B ratio from 6 (for analgesia) to
8 (for vertical forces)]. The IC50B value expressed the potency
of meloxicam to delay the disappearance of kaolin inflamma-
tion, whereas the IC50A value expressed the potency of
meloxicam to mitigate the clinical expression of the inflam-
mation (see Discussion).
Mean PK and PD parameters were used to simulate
meloxicam dosage regimens ranging from 0.05 to 2 mg/kg for
body temperature, lameness score, vertical force on a force
plate, and paw withdrawal time (Fig. 5). Considering the
maximal simulated responses, the dose-response relation-
ships were modeled (Fig. 6), and the estimated ED50 values
were calculated for the different end points. The ED50 value
was 0.0507 mg/kg for body temperature and from 0.091 to
0.127 mg/kg for the other end points.
The whole-blood ex vivo assay is useful for predicting the
clinical relevance of given levels of COX-1 and COX-2 inhi-
bition (Fig. 7). For the present experiment, it was calculated
that the plasma concentration corresponding to our esti-
mated in vivo IC50A value would ensure ex vivo an inhibition
from approximately 80 (body temperature) to 90% (others
end points) of the COX-2 isoenzyme and from 32.6 to 52.9%
of the COX-1 isoenzyme (Table 4). The in vivo COX-2
versus COX-1 selectivity, as evaluated by the ratio of COX-
2/COX-1 inhibition for a plasma concentration correspond-
ing to the in vivo IC50A value, was from 1.72 to 2.46
depending on the end point. The in vitro IC50 value (51
ng/ml) versus the in vivo IC50A ratio was from 4.1 to 10.7
depending on the end point.
Fig. 5. Simulated values of four investigated end points after a single subcutaneous meloxicam administration at 0 (placebo), 0.055, 0.1, 0.2 (thick
line), 0.3, 0.5, and 2 mg/kg b.wt. A–D, body temperature (°C) (A), lameness score (B), vertical force exerted by the paw expressed as a percentage of
the maximal observed response to kaolin (C), and paw withdrawal time expressed as a percentage of the maximal observed response to kaolin to a heat
stimulus (D). Kaolin and meloxicam were administered at 24 and 48 h, respectively. The presence of a rebound (compared with the placebo period)
is clearly seen for the four end points.
Fig. 6. Dose-response relationships for meloxicam. The effects [body
temperature (—), withdrawal time (••••) of the paw as a measure of
analgesia, and lameness score (-• -• - )] were simulated with the PK/PD
model using mean PK and PD parameters; the relationship between the
dose of meloxicam (mg/kg) and the maximal response obtained for each
dose were fitted with a inhibitory sigmoidal model (see eq. 8 in the text).
PK/PD Modeling of NSAIDs in a Dog Model 555
 at Université de Picardie Jules Verne - Service com
m
un de docum
entation on Septem
ber 15, 2011
jpet.aspetjournals.org
D
ow
nloaded from
 
Discussion
The main motivation of the present study was to develop a
humane inflammation model for preclinical PK/PD investi-
gations in dogs. The dog is a standard species for the preclin-
ical development of drugs, and its use should be ethically
acceptable. In a European Union context, this feature for an
animal model is now critically scrutinized, and a fully revers-
ible inflammatory model is considered as desirable because it
allows dogs used in this type of trial to be reallocated after
the completion of the study to other protocols or, in our case,
to be definitively rehabilitated as companion animals. Kaolin
was selected as a phlogistic agent because it acts mainly as
an inert foreign body. In rats, kaolin does not activate the
complement cascade (Noordhoek et al., 1977) but rather trig-
gers the release of kinins and prostaglandins (Lewis, 1978).
When administered outside an articulation, it is eliminable
through sterile abscess formation, an inflammation resolu-
tion that guarantees a lack of delayed side effects. This is not
the case for inflammation models having an immunological
component such as the classic Freund adjuvant arthritis
model that leads to the development of an irreversible osteo-
arthritis in dogs. In addition, we recently showed that the
subcutaneous injection of kaolin into a cat’s paw produced a
well defined, reproducible, and reversible inflammatory re-
sponse (Giraudel et al., 2005b), and this model was found to
be suitable for studying simultaneously the analgesic, anti-
inflammatory, and antipyretic effects of NSAIDs.
From the present trials, it can be concluded that the kaolin
model in dogs is ethically acceptable. It mimics the natural
process of abscess formation and maturation, and it was fully
reversible within 8 weeks. We now use this model routinely,
and we rarely observe side effects such as paw infection (one
case for 40 dogs), but limited skin necrosis is a more frequent
finding in this model.
To be useful for preclinical investigations of NSAIDs, a
canine inflammatory model should be able to predict the
order of magnitude of a future dosage regimen in different
target species including man. To assess this property, we
selected meloxicam as a test NSAID because it has been used
extensively as a therapeutic agent in both animals and hu-
mans and its dosage regimen is now well established in both
man and dogs (Engelhardt, 1996; Tu¨rck et al., 1996; Busch et
al., 1998; Slingsby and Waterman-Pearson, 2000; Lascelles
et al., 2001). In addition, the PK profile of meloxicam was
known to be very similar in man (Davies and Skjodt, 1999)
and dogs (Busch et al., 1998). This has been confirmed in the
present study where the plasma clearance determined in
dogs (Cl/F, 6.3 ml/kg per hour) can be considered as practi-
cally equal to the clearance after intravenous administration
in man (6.1 ml/kg per hour for a body weight of 70 kg) (Tu¨rck
et al., 1996). Only one meloxicam dose was investigated due
to our two-way crossover design for two hind legs with a
control and a test period, but the selected dose was likely
high enough to sweep all of the concentration-effect relation-
ship, allowing us to properly estimate PD parameters.
The main limit of this model is the lack of a prolonged
steady inflammation over several days to enable a NSAID to
be tested on a stable inflammation baseline. Indeed, the price
to pay for a reversible inflammatory model is to have inflam-
mation with a rapid time course, increasing over 2 to 3 days
and then decreasing immediately over the next few days (i.e.,
without a well defined plateau). The practical consequence of
that is the necessity to characterize precisely the time devel-
opment of the inflammation progression during a placebo
period for each tested dog and to model simultaneously the
placebo and the test period to take into account the confound-
ing factor of the natural time development of kaolin inflam-
mation. This is what we have carried out with the present
modeling approach. Several models of disease progression
were proposed (for an extensive review, see Mould, 2007). In
this study, we selected a simple Bateman function describing
the transient effect of kaolin. In fact, the time course of the
kaolin inflammation was not the same during the placebo
and test periods. For several end points, we observed a re-
Fig. 7. Ex vivo COX-1 and COX-2 inhibition in nine dogs. Relative change (0–1) against log10 blood concentrations of meloxicam in nine dogs of
thromboxane B2 as an index of COX-1 inhibition and prostaglandin E2 as an index of COX-2 inhibition (Novartis file; for details, see King et al., 2010).
TABLE 4
Extent of COX-1 and COX-2 enzyme inhibition (from 0 to 100%)
corresponding to the different estimated in vivo IC50A values
The in vivo versus in vitro potency ratio was obtained by dividing the in vivo IC50A
value (see Table 3) by the ex vivo IC50 value obtained from the whole-blood assay
i.e., 51 ng/ml (0.1454 M).
Parameters %COX-2Inhibition
%COX-1
Inhibition
In Vivo
Selectivity
Ex Vivo
IC50/In
Vivo IC50A
Ratio
Body temperature 80.1 32.6 2.46 4.1
Lameness score 89.8 52.2 1.72 9.1
Creeping time 88.4 48.3 1.83 7.8
Force plates 91.2 52.9 1.73 10.7
Analgesia 88.1 47.7 1.85 7.6
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bound effect (i.e., that after cessation of meloxicam action the
levels of paw inflammation were greater than those obtained
at the same time after placebo dosing). A possible explana-
tion for this delaying action of meloxicam on the disappear-
ance of the inflammation is the classically reported impeding
action of NSAIDs on abscess formation that is required to
physically eliminate the administered kaolin. Therefore, we
took into account in our mathematical model this effect of
meloxicam on the progression of the inflammation by modu-
lating the actual value of P2 (see eq. 4), the parameter re-
flecting the rate of inflammation disappearance. P2 was mod-
ulated by the actual meloxicam concentration through a Hill
inhibitory function (see eq. 7). This part of our model pre-
dicted that for a high meloxicam plasma concentration the
time development of the kaolin action was slowed down tem-
porarily or even stopped. It should be noted that our model is
not equivalent to classic paw edema as observed in rats after
the intra-articular administration of a phlogistic agent. In
our case, the increase in the paw volume was associated with
lymph node hypertrophy (popliteal), which can be inter-
preted as a lymphatic drainage blockade protecting the ani-
mal from systemic exposure to kaolin particles. This explains
why meloxicam (as other NSAIDs) has no short-term effect
on the paw diameter. As an alternative to this model, we also
explored a precursor-dependent indirect PD response model,
as outlined by Sharma et al. (1998), to describe tolerance and
rebound phenomena. This model fit our data well and also
was able to capture adequately the rebound phenomena.
However, it was associated with generally poor precision in
the individual estimates of IC50 values, and this was proba-
bly due to a problem of numerical identifiability. It is possible
that investigating several dose rates with a population mod-
eling approach might have rendered this kind of PK/PD
model usable, because only a single dose could be tested for
each dog based on our crossover design with two periods
(placebo and test article) corresponding to the two hind
limbs. This is a possible limitation to this paw model, because
studying a single dose rate for a NSAID may lead to some
estimation difficulties for PD parameters. This would arise
especially if the tested dose was too low. Using our PK/PD
model, we estimated the meloxicam potency for different end
points of clinical relevance, and we also confirmed the gen-
eral statement that potency is usually similar between spe-
cies (Levy, 1993; Busch et al., 1998), because the present
results are very similar to those obtained in cats using the
same model (Giraudel et al., 2005a) and in man (Davies and
Skjodt, 1999). Because the meloxicam kinetic parameters
(clearance and half-life) and meloxicam potency are very
similar in dogs and man, the present canine model should be
able to predict a relevant dosage regimen in man. In this
study, simulations for the different end points using the
PK/PD model for different dose levels allowed us to estimate
an ED50 value of 0.05 mg/kg for an antipyretic effect, an ED50
value of 0.09 for analgesia, and an ED50 value of 0.127 mg/kg
for the locomotion end points (vertical force assessed by force
plate). These doses are very similar to the current clinically
recommended dose not only in dogs (0.1 or 0.2 mg/kg) but also
in humans (7.5–15 mg, i.e., between 0.1 and 0.3 mg/kg for a
body weight of 50–70 kg). This comparison demonstrates the
potential usefulness of this preclinical PK/PD modeling ap-
proach for predicting a dosage regimen, not only in the dog as
a target species but also in other species including man. In
both instances, well designed clinical studies will be needed
to confirm or adapt the dosage regimen to clinical conditions
that might be less severe than those in this acute paw in-
flammation model.
Because the in vivo determined potencies calculated in the
present study are likely to reflect meloxicam effects on pros-
taglandin synthesis, it is relevant to compare these in vivo
IC50A values with the potency for COX-2 inhibition obtained
in vitro or ex vivo with the whole-blood assay. We showed
that the plasma concentration corresponding to our esti-
mated in vivo IC50A value would ensure, in a canine ex vivo
whole-blood assay, an inhibition of approximately 80% for
body temperature and 90% for the other end points of the
COX-2 isoenzyme. These results are consistent with what we
observed for several other NSAIDs (i.e., that an inhibition
close to 90% of the COX-2 isoenzyme is predictive of clinical
efficacy) (Toutain, 2002). Thus, the kaolin model could be
relevant for in vitro (ex vivo) to in vivo extrapolations.
In conclusion, we have developed an ethical dog inflamma-
tion model and using meloxicam as a reference NSAID. We
showed that this model would be useful to investigate dose-
effect relationships of NSAIDs and also could be relevant for
in vitro to in vivo extrapolations. The limitation of the model
is the requirement of a rather advanced PK/PD analysis to
accurately estimate the PD parameters of interest.
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